June 17, 2020 / 11:39 AM / 22 days ago

BRIEF-Cara Therapeutics Completes Interim Assessment For Kare Phase 2 Trial Of Oral Korsuva

June 17 (Reuters) - Cara Therapeutics Inc:

* CARA THERAPEUTICS ANNOUNCES COMPLETION OF INTERIM STATISTICAL ASSESSMENT FOR KARE PHASE 2 TRIAL OF ORAL KORSUVA™ IN ATOPIC DERMATITIS PATIENTS WITH MODERATE-TO-SEVERE PRURITUS

* CARA THERAPEUTICS INC - FULL TRIAL ENROLLMENT EXPECTED IN Q4 OF 2020

* CARA THERAPEUTICS INC - PATIENT ENROLLMENT INCREASED APPROXIMATELY 28% TO MAINTAIN >80% STATISTICAL POWER FOR PRIMARY ENDPOINT

* CARA THERAPEUTICS INC - BASED ON IDMC RECOMMENDATION, KARE’S TRIAL SIZE WILL BE INCREASED BY ABOUT 28% Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below